Triastek Announces Research Collaboration and Platform Technology License Agreement with BioNTech to Advance 3D Printed Oral RNA Therapeutics
2024年7月23日 - 11:13PM
ビジネスワイヤ(英語)
Triastek Inc. ("Triastek"), a global leader in 3D printing
pharmaceuticals, today announced that it has entered into a
research collaboration and platform technology license agreement
with BioNTech SE ("BioNTech"), a next generation immunotherapy
company pioneering novel therapies for cancer and other serious
diseases. Under the agreement, the companies will develop RNA
therapeutics for oral delivery based on 3D printing technology. The
collaboration aims to provide groundbreaking therapies to address
unmet medical needs in an easy to administer oral formulation.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240723000417/en/
Triastek will contribute to the collaboration its expertise in
innovative oral tablet designs made possible by 3D printing aimed
at optimizing delivery of RNA therapeutics across the
gastrointestinal mucosa, minimizing degradation in the
gastrointestinal tract, and delivering RNA therapeutics to the
portion of the gastrointestinal tract where absorption will
potentially be the greatest. Triastek's ability to create tablet
structures with unique external and internal tablet geometries,
including multiple-layer and multi-compartment designs, will be
leveraged, aiming to optimize delivery of novel RNA
therapeutics.
"We are immensely honored to announce our collaboration with
BioNTech, a leader in revolutionizing patient care with
transformative medicines," stated Dr. Senping Cheng, Founder, and
CEO of Triastek. "We believe this collaboration stands as a
promising milestone in advancing oral RNA therapeutics using 3D
printing technology and aims to set new benchmarks in the
development of large molecule oral drugs. We are committed to
working diligently together to make breakthroughs in oral delivery
of RNA therapeutics."
Under the terms of the agreement, Triastek will receive an
upfront payment of $10 million, and will be eligible to receive
development, regulatory and commercial milestone payments
potentially totaling over $1.2 billion as well as tiered royalties
on potential future product sales.
About Triastek
Founded in July 2015, Triastek is dedicated to the mission of
"revolutionizing the pharmaceutical industry, unlocking the next
generation of medicine and benefitting patients worldwide." We have
created the Melt Extrusion Deposition (MED®) 3D printing
pharmaceutical process, transforming the delivery, development, and
production of medicines through digital product development and
continuous manufacturing.
Leveraging our proprietary 3D printing pharmaceutical
technology, we design and develop transformative medicines for
patients. Through collaboration with global pharmaceutical
companies, we tackle challenging formulation problems, accelerating
the development of new drug products and improving the quality of
pharmaceuticals.
Our vision is to become the world's most influential intelligent
pharmaceutical enterprise.
About Triastek's Systematic Technology and
Applications
Triastek created the Melt Extrusion Deposition (MED®) 3D
printing pharmaceutical technology, developed and constructed a new
3D printing drug technology system, covering new
processes/equipments, new platforms, and new products, providing
end-to-end technical solutions for drug products including design,
development, manufacturing, and commercial supply.
Leveraging the MED® technology, Triastek has built three
pharmaceutical processes, which named MED® process, Melt Extrusion
Deposition plus Micro-Injection Molding (MED&MIM) process and
Melt Extrusion Deposition plus Semi-Solid Extrusion (MED&SSE)
process. Triastek has also developed five 3D microstructure drug
delivery technology platforms: Modified Release, Solubility
Enhancement, Colon Targeting, Gastric Retention, and Oral Peptide,
and developed multiple 3D printed drug product pipelines.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240723000417/en/
Public Relation Lily Chen chenshuaitong@triastek.com